Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
Rani Therapeutics Holdings (RANI) Stock Price & Analysis
183 Followers
RANI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.82 - $8.75
Previous Close$3.7
Volume47.32K
Average Volume (3M)129.11K
Market Cap
$186.55M
Enterprise Value$189.52M
Total Cash (Recent Filing)$39.58M
Total Debt (Recent Filing)$35.41M
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Aug 08, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding50,420,315
10 Day Avg. Volume64,590
30 Day Avg. Volume129,111
Standard Deviation0.32
R-Squared0.00186
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)28.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
$11.83Price Target Upside196.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Rani Therapeutics Holdings News
Bulls Say, Bears Say
Bulls Say
Market PotentialThe US obesity market is likely to be in excess of $100B at maturity, and an effective oral option like RT-114 could significantly unlock market share.
PartnershipsRani Therapeutics announced a new partnership with ProGen Therapeutics to develop RT-114, an oral obesity treatment that could unlock additional patients who are unwilling to take an injection.
TechnologyRani Therapeutics' RaniPill is a transformative technology platform that can turn any drug in the $260B biologics market into an oral format without impacting bioavailability, potentially expanding patient reach and improving compliance.
Bears Say
Development StrategyThe RT-114 development strategy adds a layer of risk by focusing on a development-stage asset instead of approved drugs.
Financial PerformanceRani reported a net loss of $0.56 per share in its 1Q24 financial results.
Regulatory And Partnership RisksThere are risks of negative data from the Phase 2 trial of RT-102 and failure to achieve regulatory approvals for key projects.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
The estimated number of people who visited one or more of the websites owned by Rani Therapeutics Holdings
Desktop Users
Mobile Users
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $1.82 and its highest was $8.75 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Currently, no data Available
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is Aug 08, 2024 which is in 22 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on May 06, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.278 by -$0.012.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate is -$0.34.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 26,303,871 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.278. Following the earnings report the stock price went down -1.323%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
---
Rani Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.83 (196.49% Upside)
$11.83 (196.49% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.94%
12-Months-Change
Fundamentals
Return on Equity
-173.56%
Trailing 12-Months
Asset Growth
-44.52%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
---
RANI Earnings Call
Q4 2024
0:00 / 0:00
---
RANI Stock 12 Month Forecast
Average Price Target
$11.83
▲(196.49% Upside)
Technical Analysis
Best Analysts Covering RANI
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+10.49%
reiterated a buy rating 24 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +10.49% per trade.
---